Kehinde Adekola
A5076933593- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Neutropenia and Cancer Infections
- Metabolism, Diabetes, and Cancer
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Iron Metabolism and Disorders
- Cancer therapeutics and mechanisms
- Cancer-related cognitive impairment studies
- Histone Deacetylase Inhibitors Research
- Cancer Treatment and Pharmacology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Pancreatic function and diabetes
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- COVID-19 and healthcare impacts
- Viral-associated cancers and disorders
Northwestern University
2016-2025
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2012-2024
Northwestern Memorial Hospital
2017-2021
Indo-American Center
2020
The University of Texas MD Anderson Cancer Center
2013-2017
University of Illinois Chicago
2017
Palmetto Hematology Oncology
2013
Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to destruction and marrow failure. This manuscript discusses the management patients with solitary plasmacytoma, smoldering multiple myeloma, newly diagnosed myeloma.
The NCCN Guidelines for Multiple Myeloma provide recommendations diagnosis, initial workup, treatment, follow-up, and supportive care patients with various plasma cell neoplasms, including multiple myeloma. These Insights highlight some of the important updates/changes specific to treatment myeloma in 2022 version guidelines.
The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These combinations with second generation proteasome inhibitors (PI); immunomodulators, monoclonal antibodies, CAR T cells, bispecific selinexor, venetoclax, and many others. Most patients MM undergo cycles remissions relapse, therefore need lines combination therapies. Selecting options for requires consideration resistance status specific classes, patient-specific factors such as age...
Abstract Purpose: We have previously demonstrated that ritonavir targeting of glycolysis is growth inhibitory and cytotoxic in a subset multiple myeloma cells. In this study, our objective was to investigate the metabolic basis resistance determine utility cotreatment with mitochondrial complex I inhibitor metformin target compensatory metabolism. Experimental Design: determined combination indices for metformin, impact on cell lines, patient samples, xenograft growth. Additional evaluation...
Primary systemic light chain amyloidosis (SLCA) is characterized by production of chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy SLCA directed recovering the function affected targeting abnormal plasma cell clone slowing deposition fibrils. NCCN Guidelines provide recommendations workup, diagnosis, treatment primary as well previously treated SLCA.
Abstract Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is main cause nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Ann Arbor (AA) scores derived from serum biomarkers at onset GVHD quantify GI crypt damage; AA2/3 correlate with resistance to treatment and higher NRM. We conducted a multicenter, phase 2 study using natalizumab, humanized monoclonal antibody that blocks T-cell trafficking through α4 subunit α4β7 integrin, combined...
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. NCCN Guidelines for WM/LPL provide a framework on which base decisions regarding diagnosis, treatment, assessment response and follow-up both newly diagnosed previously treated WM/LPL.
Chronic lymphocytic leukemia (CLL) remains fatal due to the development of resistance existing therapies. Targeting abnormal glucose metabolism sensitizes various cancer cells chemotherapy and/or elicits toxicity. Examination dependency in CLL demonstrated variable sensitivity deprivation. Further evaluation metabolic dependencies resistant deprivation revealed increased engagement fatty acid oxidation upon withdrawal. Investigation transporter expression reveals up-regulation GLUT4....
Highlights•Hematopoietic stem cell transplantation using female donor for a male recipient is associated with decreased relapse rate, yet higher nonrelapse mortality•Overall, was not improved survival patients acute myeloid leukemia•Younger high-risk leukemia may benefit from cells donorsAbstractThe mismatched minor histocompatibility antigens present on Y chromosome (H-Y) in recipients receiving donors contribute to the graft-versus-leukemia effect and results reduced especially disease. We...
Hydroxyurea has been shown to positively modify sickle cell disease pathogenesis, but its use is low among Nigerian anaemia (SCA) patients because of effectiveness and safety concerns.We conducted a quasi-experimental study evaluate the hydroxyurea in 54 SCA children aged 4-17 years. Clinical haematological parameters were compared at baseline 12 months after therapy. The participants monitored for adverse events. using relative risk Wilcoxon Signed-Rank Test.The number subjects who had more...
Highlights•Total body irradiation (TBI) is an important component of myeloablative conditioning regimens for allogeneic hematopoietic cell transplant. Long-term disease control appears to be dose-dependent, but doses > 12 Gy have previously been associated with excess toxicity and higher nonrelapse mortality (NRM).•In the current era, TBI than offer no survival advantage over standard-dose (12 Gy) when used in combination cyclophosphamide as transplant, because a decrease relapse risk offset...
Background: Hydroxyurea is underutilized by sickle cell health-care providers in Nigeria despite available evidence of its effectiveness reducing the manifestations and complications disease (SCD).
 Objectives: To assess level utilization provider-related barriers to use hydroxyurea SCD therapy Jos, Nigeria.
 Methods: A cross-sectional study conducted among 132 medical doctors providing care for patients. Data on so- cio-demographics, were obtained. The fed cumulatively into...
Limited data exist regarding the use and outcomes of allogeneic HCT in adults 70 years older. We aimed to describe trends this population utilizing reported CIBMTR from 2000-2013 US centers. 1106 recipients ≥70 (89% 70-74, 10% 75-79, <1% ≥80) 103 centers are included. The most common disease indications were AML (54%), MDS/MPN (22%), NHL (10%). 82% had KPS ≥80% 46% HCT-CI ≥3 (HCT-CI capture began 2008). Unrelated donor (URD), HLA-identical sibling (MRD), HLA-mismatched relative, umbilical...
Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention complications. We characterized the incidence of predictors being lost follow-up. Two-year survivors first allogeneic HCT (10,367 adults 3865 children) or autologous (7291 467 malignant/nonmalignant disorders between 2002 2013 reported Center International Blood Marrow Transplant Research were selected. The cumulative follow-up (defined as having missed 2 consecutive reporting...